Use of tociluzumab in the thrombocytopenic COVID-19 patient: A challenge in the therapeutic approach

.blurhash-client-img { display: none !important; }

Open Access

|Dec 2022

References

World Health Organisation, WHO Coronavirus (COVID 19) Dashboard, (Cited 2022Oct5) Available from: https://covid19.who.int/
Search in Google Scholar Back to article
McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. AutoimmunRev. 2020;19(6):102537.
Search in Google Scholar Back to article
Oldfield V, Dhillon S, Plosker GL. Tocilizumab.Drugs. 2009;69(5):609-632.
Search in Google Scholar Back to article
KewanT, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna KV,Akbik B. EClinMed. 2020;24:100418
Search in Google Scholar Back to article
Pham T,Claudepierre P, Constantin A, Bandt M, Fautrel B, Gossec L et al. Tocilizumab: Therapy and safety management. Joint Bone Spine. 2010;77:3-100.
Search in Google Scholar Back to article